Michael Skynner
Chief Scientific OfficerDr. Michael Skynner, B.Sc. Ph.D., is Chief Scientific Officer of Bicycle Therapeutics plc from January 1, 2026. Dr. Skynner served as Chief Operating Officer of Bicycle Therapeutics plc January 2018 until January 03, 2022 and was its Chief Technology Officer since January 03, 2022 until February 2026. Dr. Skynner was the Vice President of Operations at Bicycle Therapeutics plc since January 2016 until January 2018. Dr. Skynner joined Bicycle Therapeutics in January 2016 to lead operations. Prior to joining Bicycle, he led Pfizer’s rare disease efforts in Europe and founded and ran the Pfizer Rare Disease Consortium (RDC). At Pfizer, he served in molecular neuroscience group. He also established Pfizer’s Genetic Medicine Institute. Previously, he established a Discovery Performance Unit (DPU) at GSK. In his time at GSK, he successfully advanced multiple molecules from screening into clinical trials to the point of Phase IIa/b. Prior to GSK, he co-founded Cambridge Biotechnology Limited (CBT) and served as its Head of Molecular & Cellular Biology. He has 30 peer-reviewed scientific publications. Dr. Skynner is an expert in molecular neurobiology and is the inventor of micro-expression profiling, a patented CBT technology for identifying and validating novel drug targets through the amplification of mRNA from single cells. He obtained his PhD in Biochemistry at Imperial College in 1994.
Positions
- Company NameBicycle Therapeutics plcStock CodeBCYCPositionChief Scientific OfficerColleagues
- KLKevin LeeCEO & Executive Director
- FJFelix James BakerIndependent Chairman
- AMAlistair MilnesChief Corporate Development Officer
- CHChristian HeinisScientific Founder
- TTTravis ThompsonChief Financial Officer
- JGJose-Carlos Gutierrez-RamosIndependent Non-Executive Director and Member of Research & Innovation Advisory Board
- SSStephen SandsIndependent Director
- HHHerve HoppenotIndependent Director
